



# MASTER TRIAL LIST

MARCH 2022

**\*\*\*NEW & REOPENED TRIALS HIGHLIGHTED IN GREEN!\*\*\***

**JUST IN TIME TRIALS (JIT)**

AML

ANAL

ALL

APL

BLADDER-UROTHELIAL

BRAIN

BREAST/ GYN

CANCER CONTROL

CARCINOID

CLL

CML

COLON-RECTAL

ESOPHAGEAL - GASTRIC

HEAD & NECK

LYMPHOMA

MDS

MELANOMA

MERKEL

MOLECULAR STUDIES

MULTIPLE MYELOMA

NSCLC

PANCREATIC

PROSTATE

RADIATION TRIALS

RENAL CELL

SMALL CELL LUNG CANCER

VULVA

Updated 3.22.22

**RADIATION LOCATIONS:**

OSF Glen Oak - OSF main hospital

OSF Route 91 (attached to Illinois CancerCare)

UPHM - Unity Point Health Methodist

Galesburg - Western Illinois Cancer Treatment Center



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Multi-Disease Site: Advanced/Metastatic Solid Tumors**

[RAIN-3202](#)

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

**Brain**

[A021804](#)

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

[A071702](#)

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent Glioblastoma

**Breast**

[S1706](#)

**(RT not credentialed yet)**-A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

**Carcinoid**

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

**Endometrial**

[GY014](#)

**(Temp. suspended)** Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

**Gastrointestinal**

[EA2187](#)

**Temporarily closed** Phase II study of Pevonedistat in Combination with Carbo and paclitaxel in advanced intrahepatic cholangiocarcinoma.

[EA2197](#)

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

[S1922](#)

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

**Genitourinary - Rare**

|                                |   |
|--------------------------------|---|
| <a href="#"><u>A031702</u></a> | Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors ( <i>temp closed cohorts - small cell carcinoma/neuroendocrine &amp; adenocarcinoma of bladder, penile, and misc GU tract variants, renal medullary carcinoma, and rare GU</i> ) |
| <b>Head &amp; Neck</b>         |   |
| <a href="#"><u>EA3191</u></a>  | <b>Temporarily Closed (RT at Route-91)</b> A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features   |
| <b>Lung</b>                    |   |
| <a href="#"><u>S1934</u></a>   | Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. <b>NASSIST</b> (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)   |
| <b>Melanoma</b>                |   |
| <a href="#"><u>EA6192</u></a>  | A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)   |
| <a href="#"><u>S1801</u></a>   | A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma  |
| <b>Multi-Disease</b>           |   |
| <a href="#"><u>S1614</u></a>   | <i>(temp closed)</i> A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or past hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors   |
| <b>Neuroendocrine</b>          |   |
| <a href="#"><u>S2012</u></a>   | Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab In Patients w/ Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinoma (NEC)   |
| <b>Ovarian</b>                 |   |
| <a href="#"><u>GY014</u></a>   | <i>(temp closed)</i> Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma   |
| <b>Pancreas</b>                |   |
| <a href="#"><u>S2001</u></a>   | Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations  |

|                       |  |
|-----------------------|--|
| <b><u>S2104</u></b>   | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors   |
| <b>Rectal</b>         |  |
| <b><u>EA2201</u></b>  | <b>(RT at Glen Oak, UPHM, Galesburg)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma                                   |
| <b>Sarcoma</b>        |  |
| <b><u>A091902</u></b> | A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma <i>(closed to taxane pre-treated pts only)</i> |
| <b>Skin</b>           |  |
| <b><u>A091802</u></b> | Phase II randomized Trial of Avelumab plus cetuximab versus avelumab alone in advanced cutaneous Squamous cell carcinoma of skin   |
| <b>Thymoma</b>        |  |
| <b><u>S1701</u></b>   | A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma  |

# MASTER TRIAL LIST

MARCH 2022

MENU

**AML**

Navigator - Heather x3661

[Connect Myeloid](#)

The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. ***(enrolling low risk MDS only)***



# MASTER TRIAL LIST

MARCH 2022



## ANAL

Navigator - Carrie x3621

|                               |   |
|-------------------------------|---|
| <a href="#"><u>EA2176</u></a> | A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients                     |
| <a href="#"><u>EA2182</u></a> | <b>(RT at UPHM and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) |



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

MARCH 2022

[MENU](#)

*APL*

Navigator - Heather x3661

*There are no trials available at this time*



# MASTER TRIAL LIST

MARCH 2022



## ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9152](#)

A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia





# MASTER TRIAL LIST

MARCH 2022



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

### ADJUVANT / NEOADJUVANT

|                                      |  |
|--------------------------------------|--|
| <a href="#"><u>BMS CA017-078</u></a> | <b>(Peoria, Bloomington, Galesburg, and Peru)</b> -A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer ( <i>BMS-986205/placebo tablets discontinued</i> ) |
| <a href="#"><u>EA8185</u></a>        | <b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)   |
| <a href="#"><u>EA8192</u></a>        | A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy  |
| <a href="#"><u>S1806</u></a>         | <b>(RT at Glen Oak, UPHM and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer  |
| <a href="#"><u>S2011</u></a>         | Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL  |
| <b>METASTATIC</b>                    |  |
| <a href="#"><u>A031901</u></a>       | Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial   |

|                       |  |
|-----------------------|--|
| <u><b>A032002</b></u> | <b>NEW! (RT at Glen Oak)</b> Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)   |
| <u><b>S1937</b></u>   | A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy |



# MASTER TRIAL LIST

MARCH 2022



## BRAIN

Navigator - Carrie x3621

|                                     |  |
|-------------------------------------|--|
| <a href="#"><u><b>BN007</b></u></a> | <b>(RT at UPHM, Glen Oak, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma        |
| <a href="#"><u><b>BN011</b></u></a> | <b>(RT at Glen Oak)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma   |
| <a href="#"><u><b>N0577</b></u></a> | <b>(RT at Glen Oak, RT 91, and UPHM)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |



**BREAST**

Navigator - Angie x3613

**DCIS**

[AFT-25](#)

Comparing an Operation to Monitoring, With or Without Endocrine Therapy Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (**COMET**)

**NEO/ADJUVANT TREATMENT**

[S1706\\*](#)

**RT credentialing pending** - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (**All biomarker subgroups eligible**) | \*JIT TRIAL - expect 1 week delay to consent pt

**Neo/Adjuvant - HER2 Positive**

[A011801](#)

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

[EA1181](#)

Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response (CompassHER2-pCR)

**Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative**

[BR007](#)

(RT at Galesburg, Glen Oak, Rt 91, UPHM) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

**Neo/Adjuvant - Triple Negative**

No trials at this time.

**METASTATIC TREATMENT**

**Metastatic - HER2 Positive**

[BR004](#)

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

**Metastatic - Hormone Receptor Positive / HER2 Negative**

[S1703](#)

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

[S2007](#)

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases

**Metastatic - Triple Negative**

no trials at this time

**SURGERY / RADIATION ONLY**[A011202](#)**Temporarily Closed**- A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in breast Cancer Patients (cT1-3 N1) Who Have Positive Lymph Node Disease After Neoadjuvant Chemotherapy. (RT: *Glen Oak, Rt 91, UPHM, Galesburg*)[BR002](#)**Temporarily Closed** - A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Diagnosed Oligometastatic Breast Cancer (RT: *Glen Oak, UPHM*)[MA.39](#)Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (RT: *Glen Oak and UPHM*)**CANCER CONTROL (Breast only)**[A191901](#)**(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)** Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (*closed to non-black women ≥50 y/o*)[A211901](#)

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions

[A222004](#)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

[EAQ202](#)

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

[PROT001/ BLUENOTE](#)**(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa)** Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment[S1912CD](#)

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

[S2013](#)Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (**I-CHECKIT**)[URCC 16070](#)

Treatment of Refractory Nausea- for breast cancer patients.

[URCC-18007](#)Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- *at least 2 months out from surgery/tx/radiation*[WF-1901](#)

Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

**GYNECOLOGICAL**

**Navigator - Angie x3613**

|                                  |  |
|----------------------------------|--|
| <p><b><u>NRG-GY012</u></b></p>   | <p>A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer</p>             |
| <p><b><u>NRG - GY023</u></b></p> | <p>A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab</p> |
|                                  |  |
|                                  |  |
|                                  |  |
|                                  |  |
|                                  |  |

## CANCER CONTROL

### MULTI-DISEASE SITES

|                                   |  |
|-----------------------------------|--|
| <a href="#">A211901</a>           | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions   |
| <a href="#">A222004</a>           | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia   |
| <a href="#">EAQ202</a>            | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials   |
| <a href="#">PROT001/ BLUENOTE</a> | <b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa)</b> Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment |
| <a href="#">S1912CD</a>           | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)   |
| <a href="#">S2013</a>             | Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )   |
| <a href="#">WF-1901</a>           | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)   |

### BREAST

|                            |   |
|----------------------------|---|
| <a href="#">A191901</a>    | <b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, and Peru)</b> Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions ( <i>closed to non-black women ≥50 y/o</i> ) |
| <a href="#">URCC 16070</a> | Treatment of Refractory Nausea- for breast cancer patients.   |
| <a href="#">URCC-18007</a> | Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue in stage I-III Breast cancer pts.- <i>at least 2 months out from surgery/tx/radiation</i>                               |

### LUNG

Nothing currently available for Lung only - *See Multi-Disease Cancer Control trials ABOVE.*

### COLORECTAL

|                         |  |
|-------------------------|--|
| <a href="#">A221805</a> | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study   |
| <a href="#">S1820</a>   | <b>Closing 4.12.22</b>   A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC) |
| <a href="#">WF-1806</a> | (M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer  |

### BRAIN

|   |  |
|---|--|
| <a href="#"><u>WF-1801</u></a>            | A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy |
| <b>REGISTRY</b>                           |  |
| <b>Contact Disease Specific Navigator</b> |  |
| <a href="#"><u>Connect Myeloid</u></a>    | The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. <i>(enrolling low risk MDS only)</i>      |
| <a href="#"><u>NHLBI-MDS</u></a>          | <b>(Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study  |





ILLINOIS  
CANCERCARE, P.C.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

MARCH 2022

[MENU](#)

*CARCINOID*

Navigator - Ashton x3611  
Carrie x3621

*No trials at this time*

CLL

Navigator - Heather x3661

*1st Line*

|  |  |
|--|--|
| <p><u><a href="#">S1925</a></u></p>      | <p>Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): <b>EVOLVE</b> CLL/SLL Study</p> |
| <p><u><a href="#">U2-VEN-207</a></u></p> | <p><b>Temporarily Closed (Bloomington, Galesburg, Pekin, Peoria)</b> Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) in Subjects With Chronic Lymphocytic Leukemia (CLL) - <b>ULTRA-V</b></p>  |
| <p><u><a href="#">A041702</a></u></p>    | <p>A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)</p>   |

*2nd Line, 3rd Line, etc.*

|  |   |
|--|---|
| <p><u><a href="#">U2-VEN-207</a></u></p> | <p><b>Temporarily Closed (Bloomington, Galesburg, Pekin, Peoria)</b> Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax (U2-V) in Subjects With Chronic Lymphocytic Leukemia (CLL) - <b>ULTRA-V</b></p> |
|--|---|

# MASTER TRIAL LIST

MARCH 2022



*CML*

Navigator - Heather x3661

[S1712](#)

A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.

**Adjuvant**

|                                   |  |
|-----------------------------------|--|
| <a href="#"><u>A021502</u></a>    | Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair |
| <a href="#"><u>NSABP C-14</u></a> | Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )    |
| <a href="#"><u>NRG GI005</u></a>  | Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)                               |

**Metastatic**

|                                    |  |
|------------------------------------|--|
| <a href="#"><u>GI004</u></a>       | A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer  |
| <a href="#"><u>MK 7339-003</u></a> | <b>(Peoria, Bloomington, Galesburg, Peru)</b> A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) |

**CANCER CONTROL (Colorectal only)**

|                                |  |
|--------------------------------|--|
| <a href="#"><u>A211901</u></a> | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions   |
| <a href="#"><u>A221805</u></a> | Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study   |
| <a href="#"><u>A222004</u></a> | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia   |
| <a href="#"><u>EAQ202</u></a>  | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials   |
| <a href="#"><u>S1820</u></a>   | <b>Closing 4.12.22</b>   A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC) |
| <a href="#"><u>S1912CD</u></a> | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)   |

|                                |   |
|--------------------------------|---|
| <a href="#"><u>S2013</u></a>   | Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )        |
| <a href="#"><u>WF-1901</u></a> | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)                    |
| <a href="#"><u>WF-1806</u></a> | (M&M Study) Myopenia and Mechanisms of Chemotherapy Toxicity in older Adults with Colorectal Cancer |



# MASTER TRIAL LIST

MARCH 2022



## ESOPHAGEAL- GASTRIC

Navigator - Carrie x3621

|                               |   |
|-------------------------------|---|
| <a href="#"><u>EA2174</u></a> | <b>(RT at Glen Oak, RT-91, UPHM, Galesburg)</b> A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma |
| <a href="#"><u>EA2183</u></a> | <b>REOPENED! (RT at UPHM only)</b> A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)                         |

## HEAD & NECK

Navigator - Ashton x3611

|   |  |
|---|--|
| <p><a href="#"><u>EA3161</u></a></p> <p><small>SCHEMA</small></p> | <p><b>(RT at Glen Oak, UPH, Galesburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC</p>   |
| <p><a href="#"><u>EA3191 - JIT</u></a></p>                        | <p><b>Temporarily Closed (RT at Route-91)</b> A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features</p>   |
| <p><a href="#"><u>HN004</u></a></p>                               | <p><b>Temporarily Closed (RT at Glen Oak, UPHM, Galesburg)</b>-Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin</p>                   |
| <p><a href="#"><u>HN005</u></a></p>                               | <p><b>(RT at UPHM, Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer</p>   |
| <p><a href="#"><u>HN009</u></a></p>                               | <p><b>Coming Soon!</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m<sup>2</sup>) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m<sup>2</sup>) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)</p> |

## LYMPHOMA

### HL

[S1826](#)

**(RT at Glen Oak, Rt-91, UPHM)** A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age  $\geq$  12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

[SGN35-027](#)

**(Bloomington, Galesburg, Ottawa, Pekin, Peoria, Peru)** Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

### NHL

[EA4181](#)

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 Years Old With Untreated Mantle Cell Lymphoma

[TG-1501-101](#)

**(Peoria, Bloomington, Galesburg)**-A Phase 1 Study of TG-1501 in Subjects with Relapsed or Refractory Lymphoma (*classic HL cohort closed*)

### SLL





# MASTER TRIAL LIST

MARCH 2022



## MDS

Navigator - Heather x3661

|  |   |
|--|---|
| <a href="#"><u>Connect Myeloid</u></a> | The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. <i>(enrolling low risk MDS only)</i>   |
| <a href="#"><u>NHLBI-MDS</u></a>       | <b>(Peoria, Bloomington and Galesburg only)</b> -The National Myelodysplastic Syndromes (MDS) Study   |
| <a href="#"><u>M15-954</u></a>         | <b>(Peoria, Bloomington, Galesburg, Pekin)</b> A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) |



# MASTER TRIAL LIST

MARCH 2022



## MELANOMA

Navigator - Carrie x3621

|                               |  |
|-------------------------------|--|
| <a href="#"><u>EA6194</u></a> | Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination With CMP-001 in Patients With Operable Melanoma: Efficacy and Biomarker Study |
| <a href="#"><u>S2000</u></a>  | A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases             |



# MASTER TRIAL LIST

MARCH 2022

MENU

**MERKEL**

Navigator - Carrie x3621

[EA6174](#)

**(RT at Glen Oak and Rt-91 pending)** A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma



# MASTER TRIAL LIST

MARCH 2022



## MOLECULAR STUDIES

[\\*Contact Disease Specific Navigator](#)

|   |   |
|---|---|
| <a href="#"><u>2215-MA-3297 / CLEVO</u></a>         | <b>Activation Pending</b> - A non-interventional cohort study of the CLonal EVolution of <i>FLT3</i> mutations during disease progression in patients with acute myeloid leukemia - CLEVO   |
| <a href="#"><u>64091742PCR0002 / Prevalence</u></a> | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer ( <b>Prevelence</b> )   |
| <a href="#"><u>A151804</u></a>                      | Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events   |
| <a href="#"><u>NSABP C-14</u></a>                   | Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease ( <b>CORRECT-MRD II</b> )   |
| <a href="#"><u>S1823</u></a>                        | A Study of miRNA 371 in Patients With Germ Cell Tumor   |
| <a href="#"><u>TPX-0005-01 (TRIDENT-1)</u></a>      | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with <b>Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</b> (TRIDENT-1) |

# MASTER TRIAL LIST

MARCH 2022

MENU

## ***MULTIPLE MYELOMA***

Navigator - Heather x3661

|                               |  |
|-------------------------------|--|
| <a href="#"><u>EAA171</u></a> | Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)   |
| <a href="#"><u>S1803</u></a>  | Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |

NSCLC

Navigator - Ashton x3611

**ADJUVANT / NEOADJUVANT**

|                                    |  |
|------------------------------------|--|
| <a href="#"><u>A081801</u></a>     | <b>REOPENED!</b> Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ALCHEMIST substudy- <i>Must be enrolled on ALCHEMIST and this substudy prior to start of tx.</i> )   |
| <a href="#"><u>A151216</u></a>     | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial ( <b>ALCHEMIST</b> ).   |
| <a href="#"><u>EA5181</u></a>      | (RT at UPHM and Galesburg) Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC ( <b>credentialing pending at Glen Oak &amp; Rt-91</b> )  |
| <a href="#"><u>GO41854</u></a>     | (Bloomington, Galesburg, Peoria, Peoria, Peru) A Phase III, Open Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation ( <b>SKYSCRAPER-03</b> ) |
| <a href="#"><u>S1914</u></a>       | (RT at Glen Oak, UPHM, Galesburg) Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC  |
| <a href="#"><u>S1933</u></a>       | (RT at UPHM only) A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status   |
| <a href="#"><u>S1934 (JIT)</u></a> | <b>REOPENED!</b> Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer. <b>NASSIST</b> (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors)   |

**METASTATIC - 1st Line**

|   |   |
|---|---|
| <a href="#"><u>EA5163/S1709</u></a><br><a href="#"><u>INSIGNA</u></a> | <b>Temporarily Closed</b> A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis      |
| <a href="#"><u>EA5182</u></a>   | Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)  |
| <a href="#"><u>LU002</u></a>  | <b>Temporarily Closed (RT at Glen Oak, UPHM, Galesburg)</b> - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial |
| <a href="#"><u>MK 7684A-003</u></a>                                   | (Peoria only) A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer                    |
| <a href="#"><u>TH-138</u></a>   | (Peoria, Bloomington, Galesburg, Peoria) Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked ( <b>non smokers</b> )                    |

**METASTATIC - 2nd/3rd Line**

|                               |   |
|-------------------------------|---|
| <a href="#"><u>EA5191</u></a> | A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC |
|-------------------------------|---|

|                                    |   |
|------------------------------------|---|
| <u>LUNGMAP</u>                     | <p><b>NEW Sub-study!</b> A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC.</p> <p>(SUB-STUDIES: <b>S1800D</b> - A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy; <b>S1900E</b> - A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer )</p> |
| <u>MK 7684A-002</u>                | <p><b>(Peoria only)</b> A Phase II, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic NSCLC With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy.</p>  |
| <u>TH-138</u>                      | <p><b>(Peoria, Bloomington, Galesburg, Pekin)</b> Phase II Randomized Trial of Carboplatin + Pemetrexed+ Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked (<b>EGFR mutants</b>)</p>  |
| <b>CANCER CONTROL (NSCLC Only)</b> |   |
| <u>A211901</u>                     | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions  |
| <u>A222004</u>                     | A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia  |
| <u>EAQ202</u>                      | Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials  |
| <u>PROT001/ BLUENOTE</u>           | <p><b>(Peoria, Bloomington, Galesburg, Peru, Pekin and Ottawa)</b> Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment</p>   |
| <u>S1912CD</u>                     | A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention ( <b>CREDIT</b> )   |
| <u>S2013</u>                       | Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study ( <b>I-CHECKIT</b> )  |
| <u>WF-1901</u>                     | Internet-delivered Management of Pain Among Cancer Treatment Survivors ( <b>IMPACTS</b> )   |



# MASTER TRIAL LIST

MARCH 2022



## PANCREATIC

Navigator - Carrie x3621

|                                |  |
|--------------------------------|--|
| <a href="#"><u>A021806</u></a> | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer   |
| <a href="#"><u>EA2186</u></a>  | A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT) - <b><i>Drug shortage: Confirmation of Nab-Paclitaxel availability required prior to enrollment</i></b> |
| <a href="#"><u>EA2192</u></a>  | A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation ( <b>APOLLO</b> )  |



**PROSTATE**

Navigator - Carrie x3621

**ADJUVANT**

|                               |   |
|-------------------------------|---|
| <a href="#"><u>EA8183</u></a> | <b>(RT at UPHM only)</b> A Phase III Double Blinded Study of Early Intervention After RADICAL ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification ( <b>ERADICATE</b> )  |
| <a href="#"><u>GU002</u></a>  | <b>(RT at Glen Oak, UPHM, and Rt-91)</b> –Phase II-III Trial of Adjuvant radiotherapy and Androgen Deprivation Following radical Prostatectomy with or without Adjuvant Docetaxel   |
| <a href="#"><u>GU005</u></a>  | <b>(RT at Glen Oak &amp; UPHM)</b> -Phase II IGRT and SBRT vs. IGRT and hypofractionate IMRT for Localized Intermediate Risk Prostate Cancer.   |
| <a href="#"><u>GU008</u></a>  | <b>(RT at Glen Oak, UPHM; pending @ Galesburg)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i> |
| <a href="#"><u>GU009</u></a>  | <b>(RT at Glen Oak, Galesburg, UPHM; Credentialing Pending @ Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> )                             |
| <a href="#"><u>GU010</u></a>  | <b>(RT at UPHM)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)  |

**METASTATIC**

|   |   |
|---|---|
| <u><a href="#">64091742PCR0002 / Prevalence</a></u> | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer   |
| <u><a href="#">C2321001</a></u>                     | <b>(Peoria only)</b> A Phase I Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL) |
| <u><a href="#">A031902 / CASPAR</a></u>             | A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer  |
| <u><a href="#">GU011</a></u>                        | <b>Coming Soon! (RT pending @ Glen Oak , Rt 91)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)           |
| <u><a href="#">S1802</a></u>                        | <b>(RT at Glen Oak &amp; UPHM)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer                       |

# MASTER TRIAL LIST

MARCH 2022



## RENAL CELL

Navigator - Carrie x3621

|                                    |   |
|------------------------------------|---|
| <a href="#"><u>A031704</u></a>     | PD-Inhibitor (nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)   |
| <a href="#"><u>MK 6482-011</u></a> | <b>(Peoria, Bloomington, Galesburg, Pekin)</b> An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy |
| <a href="#"><u>S1931</u></a>       | Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)  |

# MASTER TRIAL LIST

MARCH 2022

MENU

## RADIATION TRIALS

Navigator - Jessica x3615

| CANCER CONTROL                 |  |
|--------------------------------|--|
| <a href="#"><u>WF-1801</u></a> | A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy   |
| ANAL                           |  |
| <a href="#"><u>EA2182</u></a>  | <b>(UPHM and Glen Oak)</b> A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)  |
| BLADDER                        |  |
| <a href="#"><u>A032002</u></a> | <b>NEW! (RT at Glen Oak)</b> Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)   |
| <a href="#"><u>EA8185</u></a>  | <b>(RT pending at Glen Oak &amp; Rt-91)</b> Phase 2 Study of Bladder-Sparing Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)   |
| <a href="#"><u>S1806</u></a>   | <b>(Glen Oak, UPHM and Galesburg)</b> Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer  |
| BRAIN                          |  |
| <a href="#"><u>BN007</u></a>   | <b>(UPHM, Glen Oak, Galesburg)</b> A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma        |
| <a href="#"><u>N0577</u></a>   | <b>(Glen Oak, RT 91, and UPHM)</b> Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |
| BRAIN METS                     |  |
| <a href="#"><u>A071801</u></a> | <b>(UPHM &amp; Glen Oak)</b> Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared With Fractionated SRS for Resected Metastatic Brain Disease   |

|                           |   |
|---------------------------|---|
| <b><u>CCTG CE.7</u></b>   | <b>(UPHM &amp; Glen Oak)-</b> A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases  |
| <b>BREAST</b>             |   |
| <b><u>A011202</u></b>     | <i>Temporarily Closed</i> <b>(Glen Oak, Rt 91, UPHM, Galesburg)</b> A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in breast Cancer Patients (cT1-3 N1) Who Have Positive Lymph Node Disease After Neoadjuvant Chemotherapy.  |
| <b><u>BR007</u></b>       | <b>(Galesburg, Glen Oak, Rt 91, UPHM)</b> Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer  |
| <b><u>MA.39</u></b>       | <b>(Glen Oak and UPHM)</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer   |
| <b>ESOPHAGEAL/GASTRIC</b> |   |
| <b><u>EA2174</u></b>      | <b>(Glen Oak, UPHM, Galesburg)</b> A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma  |
| <b><u>EA2183</u></b>      | <b>REOPENED! (UPHM only)</b> A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)   |
| <b>HEAD &amp; NECK</b>    |   |
| <b><u>EA3161</u></b>      | <b>(Glen Oak, UPH, Galeburg)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC  |
| <b><u>HN005</u></b>       | <b>(UPHM, Galesburg, Glen Oak)</b> A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer   |
| <b><u>HN009</u></b>       | <b>Coming Soon!</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| <b>HODGKIN'S LYMPHOMA</b> |   |
| <b><u>S1826</u></b>       | <b>(Glen Oak, Rt-91, UPHM)</b> A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma   |

|                               |   |
|-------------------------------|---|
| <b>MERKEL CELL</b>            |   |
| <a href="#"><u>EA6174</u></a> | <b>(UPHM and Galesburg)</b> A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma   |
| <b>NSCLC</b>                  |   |
| <a href="#"><u>EA5181</u></a> | <b>(UPHM and Galesburg)</b> Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC ( <b>credentialing pending at Glen Oak</b> )  |
| <a href="#"><u>LU002</u></a>  | <b>Temporarily Closed (Glen Oak, UPHM, Galesburg)</b> - Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial   |
| <a href="#"><u>S1914</u></a>  | <b>(Glen Oak, UPHM, Galesburg)</b> Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC  |
| <a href="#"><u>S1933</u></a>  | <b>(UPHM only)</b> A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status   |
| <b>PROSTATE</b>               |   |
| <a href="#"><u>EA8183</u></a> | <b>(RT at UPHM only)</b> A Phase III Double Blinded Study of Early Intervention After RADICAL ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification ( <b>ERADICATE</b> )  |
| <a href="#"><u>GU002</u></a>  | <b>(RT at Glen Oak, UPHM, and Rt-91)</b> –Phase II-III Trial of Adjuvant radiotherapy and Androgen Deprivation Following radical Prostatectomy with or without Adjuvant Docetaxel   |
| <a href="#"><u>GU005</u></a>  | <b>(RT at Glen Oak &amp; UPHM)</b> –Phase II IGRT and SBRT vs. IGRT and hypofractionate IMRT for Localized Intermediate Risk Prostate Cancer.   |
| <a href="#"><u>GU008</u></a>  | <b>(RT at Glen Oak, UPHM; pending @ Galesburg)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i> |

|                                       |  |
|---------------------------------------|--|
| <a href="#"><u>GU009</u></a>          | <b>(RT at Glen Oak, Galesburg, UPHM)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> ) |
| <a href="#"><u>GU010</u></a>          | <b>(RT at UPHM)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)   |
| <a href="#"><u>GU011</u></a>          | <b>Coming Soon! (RT pending @ Glen Oak , Rt 91)</b> A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiothERapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)                        |
| <a href="#"><u>S1802</u></a>          | <b>(Glen Oak &amp; UPHM)</b> Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer  |
| <a href="#"><u>WF-1802</u></a>        | <b>(Glen Oak, Rt-91, UPHM, Galesburg)</b> Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)  |
| <b>SCLC</b>                           |  |
| <a href="#"><u>NRG CC003</u></a>      | <b>(Glen Oak only)</b> Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer  |
| <a href="#"><u>NRG CC009</u></a>      | <b>(Glen Oak)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer   |
| <a href="#"><u>LU005</u></a>          | <b>(Glen Oak, UPHM and Galesburg)</b> Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab  |
| <a href="#"><u>LU007 / RAPTOR</u></a> | <b>(Glen Oak, UPHM, Galesburg)</b> – Randomized Phase II/III Trial of Consolidation RT + Immunotherapy for ES-SCLC   |
| <a href="#"><u>S1827</u></a>          | <b>(Glen Oak, UPHM, Galesburg)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer   |

## SMALL CELL LUNG CANCER

Navigator - Ashton x3611

|                                       |   |
|---------------------------------------|---|
| <a href="#"><u>NRG CC003</u></a>      | <b>(RT at Glen Oak only)</b> Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer   |
| <a href="#"><u>NRG CC009</u></a>      | <b>(RT at Glen Oak; pending at Galesburg)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer  |
| <a href="#"><u>GO43104</u></a>        | <b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab |
| <a href="#"><u>LU005</u></a>          | <b>(RT at Glen Oak, UPHM and Galesburg)</b> Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab   |
| <a href="#"><u>LU007 / RAPTOR</u></a> | <b>(RT at Glen Oak, UPHM, Galesburg)</b> – Randomized Phase II/III Trial of Consolidation RT + Immunotherapy for ES-SCLC  |
| <a href="#"><u>S1827</u></a>          | <b>(RT at Glen Oak, UPHM, Galesburg)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer  |
| <a href="#"><u>S1929</u></a>          | Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC) <i>Tissue screening allowed during induction chemotherapy</i>   |





ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

MARCH 2022



MENU

VULVA

Navigator - Angie x3613